Gemtesa Patient Assistance Program Guide (2026)

Overactive bladder (OAB) affects tens of millions of American adults, and Gemtesa (vibegron) has become a widely used treatment option since its FDA approval for OAB in 2020. With a retail price that often exceeds $500 per month, however, many patients struggle to afford it. Support programs offered through manufacturer Sumitomo Pharma America (formerly Urovant Sciences) — commonly referred to together as the Gemtesa Patient Assistance Program — are designed to lower or eliminate that cost for patients who qualify. Program names, income limits, savings caps, and prices change frequently, so treat the figures below as a starting point and confirm the current terms directly before you apply.

This article is independent educational information. FMHC is not affiliated with, endorsed by, or sponsored by Sumitomo Pharma America or any manufacturer, and we do not administer these programs.

What the Gemtesa Support Programs Offer

“Gemtesa Patient Assistance Program” is an umbrella term patients use for several distinct forms of help. Broadly, manufacturer support falls into two buckets: a copay/savings program for people who have commercial (private or employer) insurance or who are paying cash, and patient assistance (through the manufacturer or a partnering foundation) that may provide the medication at little or no cost to uninsured, lower-income patients. The exact structure and eligibility rules are set by the manufacturer and can change from year to year, so verify the current details before relying on any specific benefit.

Where a traditional patient assistance program is available, it is generally designed for people who do not have insurance coverage for the medication or who cannot afford their out-of-pocket costs. Approved patients typically receive their medication through their prescriber’s office or a designated pharmacy, with renewals based on continued need and eligibility. Because availability of a free-drug program can change, do not assume you will receive a free 90-day supply until the manufacturer confirms it in writing.

The GEMTESA Simple Savings Program

For patients with commercial insurance or who pay cash, the manufacturer’s published offering is the GEMTESA Simple Savings Program. Under its current terms (valid through December 31, 2026), eligible commercially insured patients may pay as little as $10 for a 30-day supply (up to a maximum savings of about $421 per fill) or as little as $0 for a 90-day supply (up to a maximum savings of about $1,263). Uninsured or non-covered patients may pay as little as $95 for a 30-day supply (up to a maximum savings of about $454). These figures are set by the manufacturer, vary by individual plan, and can change without notice, so confirm the current numbers before you count on them.

Crucially, savings cards like this one cannot be used by patients with government insurance — including Medicare, Medicaid, Tricare, VA benefits, or any federal or state program. They are strictly for people with private or employer-sponsored plans, or for cash-paying patients as noted above. The card is presented at the pharmacy when filling your prescription. If you are on Medicare or Medicaid, the sections below on Medicare Extra Help and other assistance are the relevant routes instead.

Eligibility Requirements (Patient Assistance)

For manufacturer or foundation patient assistance that may provide the drug at little or no cost, applicants generally must meet several criteria. You typically must be a U.S. resident or citizen. You must have a valid prescription for Gemtesa from a licensed healthcare provider. And you generally must lack insurance coverage that pays for Gemtesa — assistance is meant for the uninsured or underinsured rather than people whose plan already covers the drug.

Income eligibility for programs like this is commonly tied to a multiple of the Federal Poverty Level (FPL), often cited around 400% of FPL, though the exact cutoff varies by program and can change annually. For reference, 400% of the 2026 FPL is roughly $63,840 for an individual and about $132,000 for a family of four, based on the HHS poverty guidelines. Treat these as illustrative only: verify the current income criteria with the program, because the threshold that applies to you may differ. Patients whose income exceeds a limit but who face financial hardship from medical expenses can sometimes be considered on a case-by-case basis.

How to Apply

Any patient assistance application is prescriber-directed. Your prescribing physician completes a section confirming your diagnosis, the prescribed dosage, and the medical justification for treatment. You complete the patient portion, providing household size, income information, and supporting documentation. Physician involvement is not optional — the program relies on your clinician to verify medical need.

Required documents typically include proof of income (such as a recent tax return or recent pay stubs), a copy of your government-issued ID, and a signed attestation that you meet the eligibility criteria. Completed applications are submitted by the method the program specifies, and processing commonly takes a couple of weeks. Because forms, fax numbers, and timelines change, call the Gemtesa support line at 1-833-876-8268 (or visit Gemtesa.com) to request current forms and confirm exactly what is required for your situation.

Understanding Gemtesa and OAB

Gemtesa belongs to a class of drugs called beta-3 adrenergic agonists. It works by relaxing the bladder muscle, which can reduce symptoms of urgency, frequency, and urge incontinence. In clinical trials, vibegron reduced daily urinary urgency and incontinence episodes compared with placebo, with benefit often noticed within the first few weeks; individual results vary, and your clinician can tell you what to expect.

Unlike anticholinergic OAB medications, vibegron is not associated with the same anticholinergic cognitive burden, which is one reason clinicians sometimes favor it for older adults — though the right medication is an individual decision your prescriber should make with you. Importantly, in December 2024 the FDA expanded Gemtesa’s approval to include men with OAB symptoms who are already receiving pharmacological therapy for benign prostatic hyperplasia (BPH); it was the first beta-3 agonist approved for that specific population. If you are a man being treated for BPH, ask your clinician whether this indication applies to you.

Alternative Savings Options

If you do not qualify for manufacturer patient assistance, other avenues for savings exist. Prescription discount cards and platforms like GoodRx may offer reduced pricing at participating pharmacies, though savings on brand-name specialty drugs are often modest compared with generics, and you generally cannot combine a discount card with insurance on the same fill.

For Medicare beneficiaries, Medicare Extra Help can reduce Part D costs on covered medications, including Gemtesa if it is on your plan’s formulary. State Pharmaceutical Assistance Programs may also provide coverage for OAB medications depending on your state. The 340B pharmacy program is another option if you receive care at a qualifying health center or hospital. Medicare enrollees may also benefit from the 2026 Part D out-of-pocket cap, which limits total covered drug spending for the year.

Ask your doctor about generic alternatives as well. While there is no generic version of Gemtesa (vibegron) currently available in the U.S., older OAB medications such as oxybutynin and tolterodine are available as inexpensive generics, sometimes for only a few dollars a month. Your provider can help you weigh the clinical benefits of Gemtesa against the cost savings of generic alternatives — a decision that should be made clinically, not just financially.

Frequently Asked Questions

Can Medicare patients use the Gemtesa savings card?

Generally, no. Manufacturer copay and savings cards cannot be used by anyone with Medicare, Medicaid, Tricare, or VA coverage, due to federal rules. Medicare patients should instead explore Extra Help Medicare and their plan’s formulary, and can call the Gemtesa support line to discuss whether any assistance applies to their situation.

How long does it take to get approved?

Timelines vary by program and can change. Historically, patient assistance applications have taken roughly a couple of weeks to process once complete, but the current program is the authority on this. If you need Gemtesa sooner, ask your prescriber about sample supplies or contact the support line about expedited handling.

Do I need to reapply each year?

Typically, yes. Patient assistance programs generally require annual reapplication with updated financial documentation, and savings-card terms are often set on a calendar-year basis. Keep copies of your enrollment materials to streamline any renewal, and verify the current re-enrollment process directly.

What if I gain insurance coverage while enrolled?

If you obtain insurance that covers Gemtesa during an enrollment period, you are generally required to notify the program. Depending on the coverage, you may be transitioned to a copay card (if the new insurance is commercial) or off the program entirely. Using a free-drug program while insured for that drug typically violates program terms.

Is Gemtesa covered by most insurance plans?

Coverage varies by plan. Many commercial plans cover Gemtesa, though it may sit on a higher formulary tier with substantial copays, and some plans require prior authorization or step therapy (trying a generic OAB drug first). Your prescriber can submit a prior authorization request if your plan requires one.

Take the Next Step

Living with overactive bladder is challenging enough without the added stress of unaffordable medication. Gemtesa’s savings and patient assistance options exist to bridge the gap between the treatment you need and the cost you can bear — but the specifics change, so confirm them before you rely on them. Talk to your healthcare provider about whether assistance is right for you and about starting any application, or call 1-833-876-8268 for direct support. For additional savings strategies across all your medications, visit our healthcare costs guide.

Sources

• Sumitomo Pharma America — GEMTESA (vibegron) manufacturer and prescribing information (formerly Urovant Sciences)
• Sumitomo Pharma America press release, December 23, 2024 — FDA approval of GEMTESA for men with OAB symptoms receiving pharmacological therapy for BPH
• Gemtesa.com — GEMTESA Simple Savings Program terms and conditions (commercial vs. uninsured savings, government-insurance exclusions, support phone 1-833-876-8268)
• HHS — 2026 Federal Poverty Level guidelines (400% FPL figures)
• MedlinePlus / DailyMed — vibegron drug information and mechanism of action (beta-3 adrenergic agonist)